Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bell's Simple Linctus is an over-the-counter (OTC) cough syrup manufactured by Bell's Healthcare, primarily used for the symptomatic relief of mild, non-specific acute coughs. Its active ingredient is citric acid monohydrate (125 mg per 5 ml for adults; 31.25 mg per 5 ml in the paediatric formulation), which functions as a demulcent. The drug works through a mechanical mechanism of action, forming a soothing, protective coating over the pharyngeal mucosa to reduce throat irritation and the sensory impulse to cough. It is a standard British Pharmacopoeia (BP) preparation and is frequently utilized as an active comparator in clinical research, such as the Phase 3 trial evaluating the antitussive CS1002. The product is available without a prescription and is generally indicated for adults and children over 12 years of age, though a paediatric formulation also exists.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citric acid monohydrate.